Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Sotrovimab  COVID-19 treatment studies for Sotrovimab  C19 studies: Sotrovimab  Sotrovimab   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Progression -165% Improvement Relative Risk c19early.org/v Zaqout et al. Sotrovimab for COVID-19 EARLY TREATMENT Is early treatment with sotrovimab beneficial for COVID-19? Retrospective 928 patients in Qatar (October 2021 - February 2022) Higher progression with sotrovimab (not stat. sig., p=0.19) Zaqout et al., Int. J. Infectious Diseases, doi:10.1016/j.ijid.2022.09.023 Favors sotrovimab Favors control
Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar
Zaqout et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.09.023 (date from earlier preprint)
Zaqout et al., Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate.., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.09.023 (date from earlier preprint)
Apr 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 345 sotrovimab treated patients in Qatar matched with 583 patients that opted not to receive treatment, showing higher progression with treatment, without statistical significance.
Efficacy is variant dependent. In Vitro studies predict lower efficacy for BA.1 [Liu, Sheward, VanBlargan] and a lack of efficacy for BA.2 [Zhou]. US EUA has been revoked.
risk of progression, 164.7% higher, RR 2.65, p = 0.19, treatment 4 of 345 (1.2%), control 3 of 583 (0.5%), adjusted per study, odds ratio converted to relative risk, progression to severe/critical disease or mortality.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Zaqout et al., 21 Apr 2022, retrospective, Qatar, peer-reviewed, median age 40.0, 17 authors, study period 20 October, 2021 - 28 February, 2022.
Contact: azaqout@hamad.qa, lja2002@qatarmed.cornell.edu.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperSotrovimabAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2022.04.21.22274060; this version posted April 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Effectiveness of the neutralizing antibody sotrovimab among highrisk patients with mild to moderate SARS-CoV-2 in Qatar Ahmed Zaqout,1,2* Muna A. Almaslamani,1,2 Hiam Chemaitelly,3,4,5 Samar A. Hashim,1,2 Ajithkumar Ittaman,1,2 Abeir Alimam,1,2 Fatma Rustom,1,6 Joanne Daghfal,1 Mohammed Abukhattab,1,2 Sawsan AlMukdad,3,4 Anvar Hassan Kaleeckal,7 Ali Nizar Latif, 7 Adeel A. Butt,2,5,10 Roberto Bertollini,8 Abdullatif Al-Khal,1,2 Ali S. Omrani,1,2 and Laith J. AbuRaddad3,4,5,9* 1 Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar 3 Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar 4 World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine–Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar 5 Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA 6 Pharmacy Department, Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar 7 Hamad Medical Corporation, Doha, Qatar 8 Ministry of Public Health, Doha, Qatar 9 Department of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, Qatar 10 Department of Medicine, Weill Cornell Medicine, New York, NY and Doha, Qatar 2 * Correspondence to Dr. Ahmed Zaqout, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar, e-mail: azaqout@hamad.qa Word count: Abstract: 50 words, Main Text: 1,499 words. Number of tables: 1. Running head: Real-world effectiveness of sotrovimab in Qatar. Keywords: COVID-19; SARS-CoV-2; sotrovimab, Omicron; BA.2; variant; subvariant; casecontrol; epidemiology. 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2022.04.21.22274060; this version posted April 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Abstract Effectiveness of sotrovimab against severe, critical, or fatal COVID-19 was investigated in Qatar using a case-control study design at a time when BA.2 Omicron subvariant dominated incidence. Adjusted odds ratio of progression to severe, critical, or fatal COVID-19, comparing those sotrovimab-treated to those untreated, was 2.67-fold higher (95% CI: 0.60-11.91). 2 medRxiv preprint doi: https://doi.org/10.1101/2022.04.21.22274060; this version posted April 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Several monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed for..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit